Peter Radovich Sells 7,879 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 7,879 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the transaction, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12. This represents a 29.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Peter Radovich also recently made the following trade(s):

• On Monday, February 3rd, Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94.
• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $47.13 on Thursday. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock’s 50-day simple moving average is $47.65 and its 200 day simple moving average is $43.62. The firm has a market capitalization of $2.31 billion, a PE ratio of -23.33 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The company had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MIRM shares. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright upped their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $58.20.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Mirum Pharmaceuticals by 16.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after purchasing an additional 10,427 shares during the last quarter. Woodline Partners LP boosted its stake in shares of Mirum Pharmaceuticals by 22.2% during the fourth quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after purchasing an additional 73,399 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $897,000. Finally, Tema Etfs LLC acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $1,735,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.